Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2390727 | 0.87 | PSEN1 (0.51) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7325969 | 0.83 | ALDH1A1 (0.65) | ALDH1A1 | |
| SCHEMBL23478113 | 0.83 | PSEN1 (0.62) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL13032699 | 0.81 | ELANE (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7454391 | 0.81 | USP2 (0.48) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL13073095 | 0.79 | HTR2C (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1643399 | 0.79 | HTR2C (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL21235743 | 0.78 | ELANE (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7323415 | 0.78 | PLA2G10 (0.45) | USP2PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL31700094 | 0.77 | HTR2C (0.50) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427450-A1 | GPR 119 MODULATORS | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2427448-A1 | Gpr 119 modulators | Pfizer Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-20120052130-A1 | GPR 119 MODULATORS | PFIZER INC. | 2012-03-01 | — | — | US | disclosed |
| WO-2010128414-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128425-A1 | GPR 119 MODULATORS | PFIZER INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100285145-A1 | GPR 119 MODULATORS | PFIZER INC | 2010-11-11 | — | — | US | disclosed |
| EP-1015458-A1 | FUROPYRROLIDINE DERIVATIVES AND THEIR USE AS SERINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012936-A1 | FUROPYRROLIDINE DERIVATIVES AND THEIR USE AS SERINE PROTEASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052130-A1 | GPR 119 MODULATORS | GPR119, GPR39, GPR65 | USP2 4032/4885PSEN1 1679/4885PSEN2 1443/4885 |
| US-20100285145-A1 | GPR 119 MODULATORS | GPR119, GPR65, GPR39 | USP2 3483/4885PSEN1 1692/4885PSEN2 1486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.